

Maya Skubatch

PARTNER

Patents and
Innovations
Palo Alto

mskubatch@wsgr.com
650-849-3330



FOCUS AREAS

Biotech
Clean Energy
FoodTech and AgTech
Global Generics
Intellectual Property
Israel
Life Sciences
Medical Devices
Patents and Innovations

HIGHLIGHTS

- Strategic Patent Counselor**
Maya provides a holistic IP strategy to healthcare and other technology-driven companies.
- Comprehensive Deal Expertise**
Maya assists clients with IP matters pertaining to financings, M&A, and partnership deals.

EXPERIENCE

Maya Skubatch is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati and a former member of the firm's board of directors. Maya focuses on strategic patent counseling for both private and public life science companies. Maya works closely with licensing, litigation, corporate, and regulatory counsel to provide integrated IP strategies and often assists clients with intellectual property matters pertaining to financings, M&A, and partnership deals. Maya also works with investors on IP diligence matters.

CREDENTIALS

Education

- J.D., Santa Clara University School of Law
Intern, Affymetrix, Inc.; Extern in the chambers of the Honorable Judge Susan Illston, U.S. District Court, Northern District of California
- B.A., Molecular and Cell Biology, University of California, Berkeley
Conducted research in the laboratories of Howard Hughes Professor Randy Scheckman and Professor Sung-Ho Kim

Admissions

- State Bar of California
- Supreme Court of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Eastern District of California
- U.S. District Court for the Northern District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office

MATTERS

Select Representations

- Day One Biopharmaceuticals in intellectual property matters related to its 2021 IPO and approval of OJEMDA™ (tovorafenib) in 2024
- Hexagon Bio in intellectual property matters through its \$77 million Series B financing
- Thorne Research in *inter partes* reviews (IPRs) of US 8,383,086 US 8,197,807 related to nicotinamide riboside
- Progenity in *inter partes* review against Natera of six patents related to prenatal genetic testing
- Drawbridge in its spin out from GE and in developing its patents covering OneDraw™, a blood draw device that received FDA approval
- Labrys in developing patents covering fremanezumab (Ajovy™), a monoclonal antibody for the treatment of migraines, and its sale to Teva.
- Kythera in developing patents covering deoxycholic acid (Kybella™), currently an Allergan product
- Carmenta through its acquisition by Progenity for diagnosing pre-eclampsia
- Adverum in intellectual property matters related to its IPO and various follow-on offerings
- Verinata in intellectual property matters leading to its \$425 million acquisition by Illumina
- Ion Torrent in intellectual property matters leading to its \$725 million acquisition by Life Technologies
- Capp Medical in intellectual property matters relating to Avenio™ ctDNA testing and leading to its acquisition by Roche

INSIGHTS

Select Publications

- Co-author with H. Au, "Chapter 16: Patent Strategy – Patent Types and Considerations," *Innovation in Nephrology*, November 2024
- Co-author with D. Hoffmeister, C. Andres, D. Van Goor, and I. Dasgupta, "Dietary Supplements And FDA: Potential For Partnership?" *Law360*, March 7, 2018
- Co-author with D. Hoffmeister, V. Norviel, and C. Andres, "Complying with Expanded Access Policy Drug Laws," *Law360*, February 28, 2017
- Co-author, Brief for *amici curiae* Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, *Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al.*, On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief for *amici curiae* Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzzone, and Erin Marie Mading in support of petitioner, *Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al.*, On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief of *Amici Curiae* Amarantus Bioscience Holdings, Inc., Personalis, Inc., and Population Diagnostics, Inc. in Support of Appellants' Petition for Rehearing En Banc, *Ariosa Diagnostics, Inc. v. Sequenom, Inc.*, On Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 2014-1139, -1144
- Co-author, "A Novel Receptor for APO2L/Trail Contains a Truncated Death Domain," *Current Biology*, December 1, 1997
- Co-author, "TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," *Science* 277, August 8, 1997
- Co-author, "Herpesvirus Entry Mediator: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family Interacts with Members of the Factors NF-kB and AP," *Journal of Biological Chemistry*, Vol. 296, May 30, 1997